To date, more than 400 types of human papillomavirus (HPV) have been identified. Despite
the creation of effective prophylactic vaccines against the most common genital HPVs, the …

Although mRNA vaccines are known as potent activators of antigen-specific immune
responses against infectious diseases, limited understanding of how they drive the …

Human papillomavirus (HPV) is the most prevalent sexually transmitted virus globally.
Persistent high‐risk HPV infection can result in cervical precancerous lesions and cervical …

Human papillomaviruses, particularly high-risk human papillomaviruses, have been
universally considered to be associated with the oncogenesis and progression of various …

Tumor vaccines, as an immunotherapeutic approach, harness the body's immune cells to
provoke antitumor responses, which have shown promising efficacy in clinical settings …

Introduction Anal cancer, a rare malignancy accounting for 2.5–3.0% of gastrointestinal
cancers, primarily manifests as squamous cell carcinoma associated with HPV. Recent …

Human papillomavirus (HPV) is a major global health issue and is recognized as the
leading cause of cervical cancer. While prophylactic vaccination programs have led to …

The objective of this study was to conduct preclinical immunogenicity and efficacy studies
with several therapeutic vaccines for human papillomavirus (HPV)-16-associated cancers …

Penile cancer (PeCa) is a rare disease with poor prognosis in the metastatic stage. Neither
effective adjuvant nor palliative therapeutic options are available. Research efforts in this …

Purpose Recurrent or metastatic cervical cancer (r/m CC) presents limited treatment options
for patients failed or progressed quickly following first-line therapy. This study investigated …